Marinus Pharmaceuticals
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Radnor Corporate Center 5 Matsonford Rd ...Phone Number
(484) 801-4670Website
www.marinuspharma.comRevenue
$30.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus has initiated the first ever pivotal study in children with CDD, a rare form of epilepsy, and is currently conducting studies in patients with postpartum depression and refractory status epilepticus.Explore more
Popular SearchesMarinus PharmaceuticalsMarinus Pharmaceuticals IncMarinusMarinus IncMarinus LLCSIC Code 28,283NAICS Code 32,325Show moreMarinus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Marinus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Marinus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Marinus Pharmaceuticals
Click to see if Marinus Pharmaceuticals had a recent Job posting/layoffs
Check out if Marinus Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Marinus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Marinus Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Marinus Pharmaceuticals has new funding data
Product Launch: Get notified when Marinus Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Marinus Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Marinus Pharmaceuticals
Compare insights from companies similar to Marinus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Marinus Pharmaceuticals
$30.3M
51-200
Private
$360.2M
2003
KR
Kristin RudisillUnit Lead Acute Care Franchise Vice President, Business
Company Profile Activity
Activity Insights
Marinus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Marinus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Marinus Pharmaceuticals.
Marinus Pharmaceuticals financials insights
Gather financial insights about Marinus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series C
$21M
2014
Stock Offering
$41.3M
2015
Stock Offering
$27.7M
2017
Stock Offering
$40.3M
2018
Stock Offering
$45M
2019
Stock Offering
$70M
2022
Other Financing Round
$30M
Other Financing Round
$32.5M
Marinus Pharmaceuticals Tech Stack
A closer look at the technologies used by Marinus Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Award
Award, Finance
Marinus Pharmaceuticals News & Media
Marinus Therapeutics in Radnor Acquired by Swedish Company - DELCO.Today
Marinus Therapeutics in Radnor has been acquired by Swedish rare disease firm Immedica Pharma following layoffs.Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares are trading higher on Monday after the company entered into a merger agreement to be acquired by Immedica Pharma AB, implying an enterprise value of approximately $151 million. As per the deal, Immedica will launch a tender offer through a wholly owned subsidiary to acquire all outstanding shares of Marinus common stock at $0.55 per share in cash. This represents a 48% premium over Marinus’ December 27 closing price andSweden: Immedica to acquire all shares in Marinus Pharmaceuticals
Immedica to acquire all shares in Marinus PharmaceuticalsMRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Marinus an
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Marinus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that... Read More
